Interaction between oncodrivers and immune response has been documented in HER2+ BC, where trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) by facilitating cross-link between tumor antigen with its antigen-binding fragment and recruitment of effector cells by interaction with the Fc region (fragment crystallizable region), resulting in cytokine release and cytotoxic cell death (156). The gene discussed is ERBB2; the disease is breast cancer.